Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

RegenxBio and Pfizer Partner on Gene Therapy

Rockville, Maryland-based RegenxBio entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.

Read More »

Shares of BioCryst Fall After Phase III HAE Drug Underwhelms Investors

Shares of North Carolina-based BioCryst Pharmaceuticals were down more than 53 percent after the company released data from a Phase III trial that underwhelmed analysts.

Read More »

Shire’s Takhzyro for rare swelling disorder wins European panel green light

An EMA panel recommended approving a potential blockbuster drug from Shire Plc to treat a rare hereditary disease.

Read More »

FDA Requests Another Trial for Pharming’s Ruconest Label Expansion

The U.S. FDA issued a Complete Response Letter to Netherlands-based Pharming Group for the company’s supplemental Biologics License Application for Ruconest.

Read More »

FDA approves Shire drug for rare swelling disorder

The U.S. FDA approved a first-of-its-kind drug from Shire Plc to treat patients aged 12 and older suffering from a rare hereditary disease that causes swelling.

Read More »

FDA Grants Priority Review for Lanadelumab

Shire plc announced the U.S. Food and Drug Administration accepted the Biologics License Application and granted priority review for lanadelumab (SHP643).

Read More »

KalVista Reaches $760 Million Deal With Merck

KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.

Read More »

New Shire drug significantly reduces HAE attacks

London-listed drugmaker Shire successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE).

Read More »

CSL Behring Receives Orphan-Drug Exclusivity for Haegarda

FDA granted orphan-drug exclusivity for Haegarda for the prevention of hereditary angioedema attacks.

Read More »

Biocryst Stock Caught Fire After Reporting Positive Phase II HAE Data

Investors are cooling off on Biocryst Pharmaceuticals despite the company’s strong interim reports for its Phase II hereditary angioedema (HAE) treatment. After rising about 45 percent in premarket trading, shares of Biocryst were down more than 14 percent.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom